# Transanal versus Laparoscopic Total Mesorectal Excision in Male Patients with Low Tumor Location after Neoadjuvant Therapy: A Propensity Score-Matched Cohort Study

Authors: Ze Li; Jingkun Xiao; Yujie Hou; Xingwei Zhang; Haiqing Jie; Huashan Liu; Lei Ruan; Ziwei Zeng; Liang Kang
Journal: Gastroenterology Research and Practice
 (2022)

---

## Abstract

Background. Since Sylla and Lacy successfully reported the transanal total mesorectal excision in 2010, taTME was considered to have the potential to overcome some problematic laparoscopic cases in male, low advanced rectal cancer. However, the evidence is still lacking. This study compared the short and long outcomes of taTME with laTME in these “challenging” patients to explore the advantages of taTME among the patients. Method. After propensity score matching analysis, 106 patients were included in each group from 325 patients who met the including standard. Statistical analysis was used to compare the differences of perioperative outcomes, histopathological results, and survival results between taTME and laTME groups. Results. The mean time of pelvic operation in the taTME group was significantly shorter than in the laTME group (62.2±14.2 mins vs 81.1±18.9 mins, P=0.003). The complication incidence rate and the rate of protective loop ileostomy in the taTME group were significantly lower than those in the laTME group (19.8% vs 38.7%, P=0.003 and 70.8% vs 92.5%, P<0.001). In long-term result, there was no significant difference between the two groups for 3-year OS (87.3% vs 85.4%, P=0.86) or 3-year DFS (74.9% vs 70.1%, P=0.92). The 2-year cumulative local recurrence rate was similar between the two groups (1.1% vs 5.8%, P=0.22). Conclusion. This study demonstrated that taTME might reduce the incidence of postoperative complications, especially of anastomotic leakage in these “challenging” patients. taTME may be considered to have clear advantages for “challenging” patients.


---

## Body

## 1. Introduction

Since the concept of total mesorectum excision (TME) was described by Heald in 1979 [1], it has become a gold standard for rectal cancer surgery. According to the results of published randomized clinical trials (RCT) [2, 3], laparoscopic TME (laTME) is considered an effective alternative method to open surgery and has become the mainstream treatment for mid and low rectal cancer. Although laTME has been associated with better visualization in the pelvic cavity than open surgery, it remains challenging to perform operations in a narrow and deep space to obtain high-quality resected specimens due to fixed trocar positions and straight laparoscopic instruments [4].Since transanal total mesorectal excision (taTME) was pioneered by Sylla et al. [5], it has become a hot topic in treating middle to low rectal cancer. In comparison to laTME, taTME has a “down-to-up” and “inner-to-outer” approach. The procedure can achieve an accurate distal resection margin with great visualization during surgery [6]. Thus, it is considered a method to solve the “old problem” [7], especially in male rectal cancer patients with low tumor position or those who underwent neoadjuvant therapy. Herein, we define a patient featured by all of the above conditions as a “challenging” patient. In such patients, sufficient free space cannot be obtained when dissociating from head-to-tail due to more curved sacrum and pelvic tissue edema [8]. Furthermore, “challenging” patients not only present a higher risk of complications during laparoscopic surgery but also feature undesired mesorectal resection quality and status of the resection margin, which may lead to poor prognosis such as local recurrence [9]. While the “down-to-up” approach in taTME has been considered to largely overcome these difficult aspects of open surgery or laparoscopic surgery [7], studies reporting taTME results for “challenging” patients are still lacking. Therefore, the specific aim of the present study was to explore the advantages of taTME among “challenging” patients by comparing the outcomes of taTME with laTME performed in such patients.


## 2. Methods

### 2.1. Patients

All consecutive clinical records of patients who underwent taTME performed by experienced surgeons with two groups in the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) from July 2014 to July 2020 were reviewed. The inclusion criteria were as follows: (1) male, (2) history of neoadjuvant therapy, and (3)tumorlocation<5cm from the anal margin. Female patients, underwent emergency surgery or abdominoperineal resection, were excluded from this study. Subsequently, this cohort was matched with patients who underwent laTME performed by experienced surgeons in our center by propensity score matching (PSM), which can minimize selection bias caused by the retrospective analysis [10, 11].Baseline characteristics were regarded as the covariates that may impact selection bias in the retrospective analysis, including age, body mass index (BMI), preoperative incomplete intestinal obstruction, history of past abdominal surgery, tumor location, tumor size, tumor stage, and type of neoadjuvant therapy regimen.


### 2.2. Measured Outcomes

Data were collected in specific tables by referring to medical records and the institutional prospective colorectal cancer database. The baseline demographic and clinical data were the same as the covariates. For preoperative staging, enhanced CT and MR imaging (or endorectal ultrasound) have been used. If the patient underwent neoadjuvant radiotherapy, the surgery was planned for a minimum of 8 weeks after the last radiotherapy.Perioperative outcomes are defined as surgery-related outcomes, including total operative time, pelvis operative time, intraoperative blood loss, conversion rate, protective loop ileostomy rate, postoperative complication, postoperative hospital stay, and 30-day postoperative mortality. The Clavien-Dindo classification was used to categorize the early postoperative complications [12]. In this study, pelvic operative time in the taTME group was defined as the time from the beginning of the purse-string suture (Figure 1(a)) to the completion of TME by opening the peritoneum reflection (Figure 1(b)). Meanwhile, the time in the laTME group was from the incision peritoneal reflection on the anterior lateral side (Figure 1(c)) or the separation of the S2 level on the posterior side to the plane of the levator anus muscle, to cutting off the bowel at the distal tumor edge (Figure 1(d)). Protective loop ileostomy depends on the blood supply and edema of the anastomotic stoma. Within the first 30 days following surgery, any clinical or radiological evidence of a defect of the anastomotic stoma was considered an anastomotic leak. All patients get an MRI in regular follow-up.Figure 1
(a) Beginning of the purse-string suture. (b) Completion of TME by the opening of the peritoneum reflection. (c) Incision peritoneal reflection on the anterior lateral sided. (d) After cutting off the bowel at the distal tumor edge.
(a)(b)(c)(d)Pathological outcomes include the quality of the mesorectal specimen, the distance between tumor and distal resection margin, distal resection margin (DRM) status, number of harvested lymph nodes, and circumferential resection margin (CRM) involvement. A negative radial resection margin was defined as greater than 1 mm distance between the tumor or malignant lymph node and CRM [13, 14]. The quality of the mesorectum specimen was classified into three grades: (i) incomplete, (ii) nearly complete, and (iii) complete [15]. Tumors were staged by the TNM classification (8th edition) [16].


### 2.3. Statistical Analysis

All analyseswere carried out using the Statistical Package for the Social Sciences Software (v26.0; SPSS Inc, Chicago, IL, USA). First, the normal distribution of continuous variables was tested by the Shapiro-Wilk test. Next, the normal distribution of continuous variables was described as mean±standarddeviation (range) and analyzed using the independent samples t-test. The abnormal distribution of continuous variables was presented as median (range) and analyzed using the Mann–Whitney U test. Categorical variables were reported as the number of patients (percentage) and compared by the χ2 test or the Fisher’s exact test. A P value of less than 0.05 was defined as statistically significant. A propensity score was calculated by a logistic regression model for the variables shown in Table 1. Propensity score matching was then used with a 1 : 1 nearest neighbor matching algorithm. Unmatched patients were excluded. A caliper distance of 0.1 of the pooled standard deviation of the logit of the propensity score was applied.Table 1
Demographic and clinical data before and after propensity score matching.
CharacteristicsBefore propensity score matchingPAfter propensity score matchingPtaTME (n=112)laTME (n=213)taTME (n=106)laTME (n=106)Age,mean±SD (range)56±12 (23-78)53±12 (20-80)0.0855±12 (23-78)56±12 (26-79)0.80BMI,mean±SD (range)23.0±2.9 (17.1-37.6)22.5±3.0 (15.9-34.2)0.1023.0±2.9 (17.2-32.3)22.9±3.2 (16.9-34.3)0.85Tumor location,mean±SD (range)3.5±0.9 (1.0-5.0)3.9±0.9 (1.4-5.0)<0.0013.6±0.9 (2.0-5.0)3.8±0.9 (1.4-5.0)0.20Tumor size (cm),mean±SD (range)3.0±1.3 (0.3-6.6)2.7±1.7 (0-8.0)0.073.0±1.3 (0.3-6.6)2.8±2.0 (0-8.0)0.20Preoperative intestinal obstruction,n (%)<0.001—None112 (100%)199 (93.4%)106 (100%)106 (100%)Incomplete0 (0%)14 (6.6%)——History of past abdominal surgery,n (%)0.681.00Without105 (93.8%)202 (94.8%)101 (95.3%)102 (96.2%)With7 (6.3%)11 (5.2%)5 (4.7%)4 (3.8%)cT,n (%)0.230.53T00 (0%)1 (0.5%)——T11 (0.9%)1 (0.5%)1 (0.9%)0 (0%)T212 (10.7%)41 (19.2%)12 (11.3%)18 (17.0%)T390 (80.4%)156 (73.2%)86 (81.1%)82 (77.4%)T49 (8%)14 (6.6%)7 (6.6%)6 (5.7%)cN,n (%)0.090.63N063 (56.3%)145 (68.1%)60 (56.6%)66 (62.3%)N133 (29.5%)47 (22.1%)31 (29.2%)25 (23.6%)N216 (14.3%)21 (9.9%)15 (14.2%)15 (14.2%)cM,n (%)0.241.00M0108 (96.4%)210 (98.6%)102 (96.2%)103 (97.2%)M14 (3.6%)3 (1.4%)4 (3.8%)3 (2.8%)Type of neoadjuvant therapy regimen,n (%)<0.0010.47Only chemotherapy77 (68.8%)89 (41.8%)71 (67.0%)66 (62.3%)Radiochemotheraoy35 (31.3%)121 (56.8%)35 (33.0%)40 (37.7%)Only radiotherapy0(0%)3(1.4%)——


## 2.1. Patients

All consecutive clinical records of patients who underwent taTME performed by experienced surgeons with two groups in the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) from July 2014 to July 2020 were reviewed. The inclusion criteria were as follows: (1) male, (2) history of neoadjuvant therapy, and (3)tumorlocation<5cm from the anal margin. Female patients, underwent emergency surgery or abdominoperineal resection, were excluded from this study. Subsequently, this cohort was matched with patients who underwent laTME performed by experienced surgeons in our center by propensity score matching (PSM), which can minimize selection bias caused by the retrospective analysis [10, 11].Baseline characteristics were regarded as the covariates that may impact selection bias in the retrospective analysis, including age, body mass index (BMI), preoperative incomplete intestinal obstruction, history of past abdominal surgery, tumor location, tumor size, tumor stage, and type of neoadjuvant therapy regimen.


## 2.2. Measured Outcomes

Data were collected in specific tables by referring to medical records and the institutional prospective colorectal cancer database. The baseline demographic and clinical data were the same as the covariates. For preoperative staging, enhanced CT and MR imaging (or endorectal ultrasound) have been used. If the patient underwent neoadjuvant radiotherapy, the surgery was planned for a minimum of 8 weeks after the last radiotherapy.Perioperative outcomes are defined as surgery-related outcomes, including total operative time, pelvis operative time, intraoperative blood loss, conversion rate, protective loop ileostomy rate, postoperative complication, postoperative hospital stay, and 30-day postoperative mortality. The Clavien-Dindo classification was used to categorize the early postoperative complications [12]. In this study, pelvic operative time in the taTME group was defined as the time from the beginning of the purse-string suture (Figure 1(a)) to the completion of TME by opening the peritoneum reflection (Figure 1(b)). Meanwhile, the time in the laTME group was from the incision peritoneal reflection on the anterior lateral side (Figure 1(c)) or the separation of the S2 level on the posterior side to the plane of the levator anus muscle, to cutting off the bowel at the distal tumor edge (Figure 1(d)). Protective loop ileostomy depends on the blood supply and edema of the anastomotic stoma. Within the first 30 days following surgery, any clinical or radiological evidence of a defect of the anastomotic stoma was considered an anastomotic leak. All patients get an MRI in regular follow-up.Figure 1
(a) Beginning of the purse-string suture. (b) Completion of TME by the opening of the peritoneum reflection. (c) Incision peritoneal reflection on the anterior lateral sided. (d) After cutting off the bowel at the distal tumor edge.
(a)(b)(c)(d)Pathological outcomes include the quality of the mesorectal specimen, the distance between tumor and distal resection margin, distal resection margin (DRM) status, number of harvested lymph nodes, and circumferential resection margin (CRM) involvement. A negative radial resection margin was defined as greater than 1 mm distance between the tumor or malignant lymph node and CRM [13, 14]. The quality of the mesorectum specimen was classified into three grades: (i) incomplete, (ii) nearly complete, and (iii) complete [15]. Tumors were staged by the TNM classification (8th edition) [16].


## 2.3. Statistical Analysis

All analyseswere carried out using the Statistical Package for the Social Sciences Software (v26.0; SPSS Inc, Chicago, IL, USA). First, the normal distribution of continuous variables was tested by the Shapiro-Wilk test. Next, the normal distribution of continuous variables was described as mean±standarddeviation (range) and analyzed using the independent samples t-test. The abnormal distribution of continuous variables was presented as median (range) and analyzed using the Mann–Whitney U test. Categorical variables were reported as the number of patients (percentage) and compared by the χ2 test or the Fisher’s exact test. A P value of less than 0.05 was defined as statistically significant. A propensity score was calculated by a logistic regression model for the variables shown in Table 1. Propensity score matching was then used with a 1 : 1 nearest neighbor matching algorithm. Unmatched patients were excluded. A caliper distance of 0.1 of the pooled standard deviation of the logit of the propensity score was applied.Table 1
Demographic and clinical data before and after propensity score matching.
CharacteristicsBefore propensity score matchingPAfter propensity score matchingPtaTME (n=112)laTME (n=213)taTME (n=106)laTME (n=106)Age,mean±SD (range)56±12 (23-78)53±12 (20-80)0.0855±12 (23-78)56±12 (26-79)0.80BMI,mean±SD (range)23.0±2.9 (17.1-37.6)22.5±3.0 (15.9-34.2)0.1023.0±2.9 (17.2-32.3)22.9±3.2 (16.9-34.3)0.85Tumor location,mean±SD (range)3.5±0.9 (1.0-5.0)3.9±0.9 (1.4-5.0)<0.0013.6±0.9 (2.0-5.0)3.8±0.9 (1.4-5.0)0.20Tumor size (cm),mean±SD (range)3.0±1.3 (0.3-6.6)2.7±1.7 (0-8.0)0.073.0±1.3 (0.3-6.6)2.8±2.0 (0-8.0)0.20Preoperative intestinal obstruction,n (%)<0.001—None112 (100%)199 (93.4%)106 (100%)106 (100%)Incomplete0 (0%)14 (6.6%)——History of past abdominal surgery,n (%)0.681.00Without105 (93.8%)202 (94.8%)101 (95.3%)102 (96.2%)With7 (6.3%)11 (5.2%)5 (4.7%)4 (3.8%)cT,n (%)0.230.53T00 (0%)1 (0.5%)——T11 (0.9%)1 (0.5%)1 (0.9%)0 (0%)T212 (10.7%)41 (19.2%)12 (11.3%)18 (17.0%)T390 (80.4%)156 (73.2%)86 (81.1%)82 (77.4%)T49 (8%)14 (6.6%)7 (6.6%)6 (5.7%)cN,n (%)0.090.63N063 (56.3%)145 (68.1%)60 (56.6%)66 (62.3%)N133 (29.5%)47 (22.1%)31 (29.2%)25 (23.6%)N216 (14.3%)21 (9.9%)15 (14.2%)15 (14.2%)cM,n (%)0.241.00M0108 (96.4%)210 (98.6%)102 (96.2%)103 (97.2%)M14 (3.6%)3 (1.4%)4 (3.8%)3 (2.8%)Type of neoadjuvant therapy regimen,n (%)<0.0010.47Only chemotherapy77 (68.8%)89 (41.8%)71 (67.0%)66 (62.3%)Radiochemotheraoy35 (31.3%)121 (56.8%)35 (33.0%)40 (37.7%)Only radiotherapy0(0%)3(1.4%)——


## 3. Results

Among all 2309 patients, 325 patients met the set standard, including 213 in the laTME group and 112 in the taTME group. Eventually, 106 patients were included per group for further analysis after PSM (Figure2).Figure 2
Flow chart of patient selection.


### 3.1. Prematching and Postmatching of Baseline Characteristics

The details of the 1 : 1 PSM process are shown in Figure2. After matching, demographic and clinical data between the two groups became more balanced, as described in Table 1. Moreover, no significant differences were shown between the two groups regarding the baseline demographic and clinical data.


### 3.2. Perioperative Outcomes

Results on perioperative outcomes are summarized in Table2. No intraoperative complications occurred in either group. The average pelvis operative time was significantly less in the taTME group as compared with the laTME group (62.2±14.2 min vs 81.1±18.9 min, P=0.003). The mean intraoperative bleeding loss in the taTME group was less than that in the laTME group (90±156 mL vs 103±136 mL, P=0.004). The protective loop ileostomy rate was significantly lower in the taTME group (70.8% vs 92.5%, P<0.001). In addition, the mean distance between anastomosis and the anal margin was larger in this group (2.3±1.0 cm vs 2.0±1.1 cm, P=0.051). It is worth noting that there were three cases of conversion to taTME and open surgery in the laTME group. Two of these cases were converted to taTME because the pelvic stenosis resulted in an unclear surgical field and excessive bleeding that could not continue the separation. In a further case, open surgery was opted for due to inadequate blood supply of the proximal intestinal tube during anastomosis and the difficulty in redissociating the splenic flexure. The overall rate of postoperative complications was significantly lower in the taTME group than in the laTME group (19.8% vs 38.7%, P=0.003), especially the anastomotic leakage rate (14.2% vs 25.2%, P=0.017). Moreover, the median hospital stay after taTME was one day shorter than after laTME (9 days vs 10 days, P<0.001).Table 2
Perioperative outcomes.
CharacteristicsGroupPtaTME (n=106)laTME (n=106)Total operative time minutes(min)mean±SD (range)225.0±81.5 (102-600)241.1±88.6 (105-586)0.425Pelvic operative time minutes(min)mean±SD (range)62.2±14.2 (43-98)81.1±18.9 (55-178)0.003Intraoperative blood loss(mL),mean±SD (range)90±156 (10-1500)103±136 (20-1300)0.004Blood transfusion,n (%)1Yes2 (98.1%)2 (98.1%)No104 (1.9%)104 (1.9%)Distance from anastomosis to anal margin(cm),mean±SD (range)2.3±1.0 (0-5)2.0±1.1 (0-5)0.051Protective loop ileostomy,n (%)<0.001Yes75 (70.8%)98 (92.5%)No31 (29.2%)8 (7.5%)Conversion,n (%)0.246Yes—3 (2.8%)No106 (100.0%)103 (97.2%)Postoperative transfer to ICU,n (%)1Yes3 (2.8%)3 (2.8%)No103 (97.2%)103 (97.2%)Postoperative complication,n (%)0.003Yes21 (19.8%)41 (38.7%)No85 (80.2%)65 (61.3%)Types of complications,n (%)Anastomotic leakage15 (14.2%)27 (25.2%)0.017Postoperative ileus2 (0.9%)5 (4.7%)0.445Anastomotic stenosis5 (4.7%)5 (4.7%)1Postoperative abdominal hemorrhage—1 (0.9%)Rectourethral fistula1 (0.9%)2 (0.9%)1Urinary retention2 (0.9%)6 (5.7%)0.28Pulmonary infections—1 (0.9%)Pelvic abscess—1 (0.9%)Anastomotic ischemic enteritis—1 (0.9%)Clavien-Dindo grade,n (%)a0.03I/II14 (66.7%)30 (73.2%)0.593III7 (33.3%)9 (22.0%)0.332IV—1 (2.4%)V—1 (2.4%)Postoperative hospital stay (days), median (range)9 (3-48)10 (6-30)<0.00130-day postoperative mortality,n (%)1Yes—1 (0.9%)No106 (100.0%)105 (99.1%)aProportion of patients with postoperative complications in each group: 21 (taTME group) and 41 (laTME group).


### 3.3. Pathological Results

Detailed data obtained on histopathological outcomes are depicted in Table3. According to histopathological results, the majority of patients had T3 or N0 lesions. In the taTME group, the mean distance between the inferior tumor and the distal margin was shorter (1.2±0.9 cm) compared with the laTME group (1.3±1.9 cm). However, the difference did not reach statistical significance (P=0.394). In addition, the DRM was positive in one case (1.5%) in each group. No patients had positive CRM in the taTME group, while two patients (3.0%) in the laTME group presented positive CRM (P=0.498). These two patients both had T4 lesions, were featured by the preoperative staging of T3, and underwent neoadjuvant radiochemotherapy treatment. In terms of mesorectal specimen quality, even though the complete resection rate in the taTME group was higher than that in the laTME group, the difference was not statistically significant (95.3% vs 91.5%, P=0.269).Table 3
Pathological outcomes.
CharacteristicsGroupPtaTME(n=106)laTME(n=106)Length of resected intestine in centimeters (cm),mean±SD (range)12.6±4.7 (7.0-34.0)13.1±5.1 (6.5-36.0)0.458Quality of the mesorectum specimen0.269Complete101 (95.3%)97 (91.5%)Nearly complete5 (4.7%)9 (8.5%)Distance between tumor and distal resection margin in cm,mean±SD (range)1.2±0.9 (0.1-4.5)1.3±1.9 (0.2-4.0)0.394Number of harvested lymph nodes, median (range)13 (1-38)12 (0-38)0.285DRM status,n (%)1Negative105 (99.1%)105 (99.1%)Positive1 (0.9%)1 (0.9%)Lymphovascular invasion,n (%)0.683Negative102 (96.2%)104 (98.1%)Positive4 (3.8%)2 (5.7%)Perineural invasion,n (%)0.422Negative97 (91.5%)100 (94.3%)Positive9 (8.5%)6 (5.7%)CRM status,n (%)0.498Negative106 (100%)104 (98.1%)Positive0 (0%)2 (1.9%)pT,n (%)0.074PCR16 (15.1%)24 (22.6%)T13 (2.8%)8 (7.5%)T219 (17.9%)21 (19.8%)T367 (63.2%)49 (46.2%)T41 (0.9%)4 (3.8%)pN,n (%)0.17N077 (72.6%)79 (74.5%)N117 (16%)22 (20.8%)N212 (11.3%)5 (4.7%)pM,n (%)0.7213M0101 (95.3%)103 (97.2%)M15 (4.7%)3 (2.8%)


### 3.4. Follow-Up

The median follow-up time of the taTME and laTME patients was21.80±18.153 (1-121) months and 30.29±13.439 (1-73) months, respectively. As shown in Figures 3(a) and 3(b), there was no significant difference between the two groups for 3-year OS (87.3% VS 85.4%, P=0.86) or 3-year DFS (74.9% vs 70.1%, P=0.92). The 2-year cumulative local recurrence rate (Figure 3(c)) was similar between the two groups (1.1% vs 5.8%, P=0.22). Within 2 years after surgery, in the taTME group, one patient had a local recurrence 5 months after the operation shortly, and the patient just received palliative chemotherapy, at last. In the laTME group, 5 patients presented local recurrence at 10, 12, 15, 22, and 24 months after surgery, respectively, within the 2-year follow-up period.Figure 3
Kaplan–Meier plots of overall survival (a). Kaplan–Meier plots of disease-free survival (b). Kaplan–Meier plots of free-local recurrent (c).
(a)(b)(c)


## 3.1. Prematching and Postmatching of Baseline Characteristics

The details of the 1 : 1 PSM process are shown in Figure2. After matching, demographic and clinical data between the two groups became more balanced, as described in Table 1. Moreover, no significant differences were shown between the two groups regarding the baseline demographic and clinical data.


## 3.2. Perioperative Outcomes

Results on perioperative outcomes are summarized in Table2. No intraoperative complications occurred in either group. The average pelvis operative time was significantly less in the taTME group as compared with the laTME group (62.2±14.2 min vs 81.1±18.9 min, P=0.003). The mean intraoperative bleeding loss in the taTME group was less than that in the laTME group (90±156 mL vs 103±136 mL, P=0.004). The protective loop ileostomy rate was significantly lower in the taTME group (70.8% vs 92.5%, P<0.001). In addition, the mean distance between anastomosis and the anal margin was larger in this group (2.3±1.0 cm vs 2.0±1.1 cm, P=0.051). It is worth noting that there were three cases of conversion to taTME and open surgery in the laTME group. Two of these cases were converted to taTME because the pelvic stenosis resulted in an unclear surgical field and excessive bleeding that could not continue the separation. In a further case, open surgery was opted for due to inadequate blood supply of the proximal intestinal tube during anastomosis and the difficulty in redissociating the splenic flexure. The overall rate of postoperative complications was significantly lower in the taTME group than in the laTME group (19.8% vs 38.7%, P=0.003), especially the anastomotic leakage rate (14.2% vs 25.2%, P=0.017). Moreover, the median hospital stay after taTME was one day shorter than after laTME (9 days vs 10 days, P<0.001).Table 2
Perioperative outcomes.
CharacteristicsGroupPtaTME (n=106)laTME (n=106)Total operative time minutes(min)mean±SD (range)225.0±81.5 (102-600)241.1±88.6 (105-586)0.425Pelvic operative time minutes(min)mean±SD (range)62.2±14.2 (43-98)81.1±18.9 (55-178)0.003Intraoperative blood loss(mL),mean±SD (range)90±156 (10-1500)103±136 (20-1300)0.004Blood transfusion,n (%)1Yes2 (98.1%)2 (98.1%)No104 (1.9%)104 (1.9%)Distance from anastomosis to anal margin(cm),mean±SD (range)2.3±1.0 (0-5)2.0±1.1 (0-5)0.051Protective loop ileostomy,n (%)<0.001Yes75 (70.8%)98 (92.5%)No31 (29.2%)8 (7.5%)Conversion,n (%)0.246Yes—3 (2.8%)No106 (100.0%)103 (97.2%)Postoperative transfer to ICU,n (%)1Yes3 (2.8%)3 (2.8%)No103 (97.2%)103 (97.2%)Postoperative complication,n (%)0.003Yes21 (19.8%)41 (38.7%)No85 (80.2%)65 (61.3%)Types of complications,n (%)Anastomotic leakage15 (14.2%)27 (25.2%)0.017Postoperative ileus2 (0.9%)5 (4.7%)0.445Anastomotic stenosis5 (4.7%)5 (4.7%)1Postoperative abdominal hemorrhage—1 (0.9%)Rectourethral fistula1 (0.9%)2 (0.9%)1Urinary retention2 (0.9%)6 (5.7%)0.28Pulmonary infections—1 (0.9%)Pelvic abscess—1 (0.9%)Anastomotic ischemic enteritis—1 (0.9%)Clavien-Dindo grade,n (%)a0.03I/II14 (66.7%)30 (73.2%)0.593III7 (33.3%)9 (22.0%)0.332IV—1 (2.4%)V—1 (2.4%)Postoperative hospital stay (days), median (range)9 (3-48)10 (6-30)<0.00130-day postoperative mortality,n (%)1Yes—1 (0.9%)No106 (100.0%)105 (99.1%)aProportion of patients with postoperative complications in each group: 21 (taTME group) and 41 (laTME group).


## 3.3. Pathological Results

Detailed data obtained on histopathological outcomes are depicted in Table3. According to histopathological results, the majority of patients had T3 or N0 lesions. In the taTME group, the mean distance between the inferior tumor and the distal margin was shorter (1.2±0.9 cm) compared with the laTME group (1.3±1.9 cm). However, the difference did not reach statistical significance (P=0.394). In addition, the DRM was positive in one case (1.5%) in each group. No patients had positive CRM in the taTME group, while two patients (3.0%) in the laTME group presented positive CRM (P=0.498). These two patients both had T4 lesions, were featured by the preoperative staging of T3, and underwent neoadjuvant radiochemotherapy treatment. In terms of mesorectal specimen quality, even though the complete resection rate in the taTME group was higher than that in the laTME group, the difference was not statistically significant (95.3% vs 91.5%, P=0.269).Table 3
Pathological outcomes.
CharacteristicsGroupPtaTME(n=106)laTME(n=106)Length of resected intestine in centimeters (cm),mean±SD (range)12.6±4.7 (7.0-34.0)13.1±5.1 (6.5-36.0)0.458Quality of the mesorectum specimen0.269Complete101 (95.3%)97 (91.5%)Nearly complete5 (4.7%)9 (8.5%)Distance between tumor and distal resection margin in cm,mean±SD (range)1.2±0.9 (0.1-4.5)1.3±1.9 (0.2-4.0)0.394Number of harvested lymph nodes, median (range)13 (1-38)12 (0-38)0.285DRM status,n (%)1Negative105 (99.1%)105 (99.1%)Positive1 (0.9%)1 (0.9%)Lymphovascular invasion,n (%)0.683Negative102 (96.2%)104 (98.1%)Positive4 (3.8%)2 (5.7%)Perineural invasion,n (%)0.422Negative97 (91.5%)100 (94.3%)Positive9 (8.5%)6 (5.7%)CRM status,n (%)0.498Negative106 (100%)104 (98.1%)Positive0 (0%)2 (1.9%)pT,n (%)0.074PCR16 (15.1%)24 (22.6%)T13 (2.8%)8 (7.5%)T219 (17.9%)21 (19.8%)T367 (63.2%)49 (46.2%)T41 (0.9%)4 (3.8%)pN,n (%)0.17N077 (72.6%)79 (74.5%)N117 (16%)22 (20.8%)N212 (11.3%)5 (4.7%)pM,n (%)0.7213M0101 (95.3%)103 (97.2%)M15 (4.7%)3 (2.8%)


## 3.4. Follow-Up

The median follow-up time of the taTME and laTME patients was21.80±18.153 (1-121) months and 30.29±13.439 (1-73) months, respectively. As shown in Figures 3(a) and 3(b), there was no significant difference between the two groups for 3-year OS (87.3% VS 85.4%, P=0.86) or 3-year DFS (74.9% vs 70.1%, P=0.92). The 2-year cumulative local recurrence rate (Figure 3(c)) was similar between the two groups (1.1% vs 5.8%, P=0.22). Within 2 years after surgery, in the taTME group, one patient had a local recurrence 5 months after the operation shortly, and the patient just received palliative chemotherapy, at last. In the laTME group, 5 patients presented local recurrence at 10, 12, 15, 22, and 24 months after surgery, respectively, within the 2-year follow-up period.Figure 3
Kaplan–Meier plots of overall survival (a). Kaplan–Meier plots of disease-free survival (b). Kaplan–Meier plots of free-local recurrent (c).
(a)(b)(c)


## 4. Discussion

It remains difficult worldwide to achieve a high standard of TME to treat low rectal cancer male patients that underwent neoadjuvant therapy [2, 17]. The taTME procedure has been considered to have the potential to solve this problem [7]. In this study, we compared the performance of taTME and laTME in “challenging” patients. Results showed that taTME could reduce pelvis operative time and intraoperative blood loss. Furthermore, the number of patients with protective loop ileostomy and postoperative complications proved to be significantly lower in the taTME group than in the laTME group. Most importantly, taTME also showed potential in achieving high-quality resected specimens and great long-term results in “challenging” patients.In this study, the pelvic operative time of taTME was shorter than that of laTME, and the intraoperative blood loss was also reduced compared with laTME. This may reflect that laparoscopic surgery still fails to solve the exposure problem in pelvic surgery for “challenging” patients, as it is too difficult to perform complex operations in the deep pelvis with rigid straight laparoscopic instruments [18–20], and it is also hard to obtain adequate traction of the rectum [21]. Moreover, patients after neoadjuvant therapy are generally prone to bleeding, resulting in the declined clarity of visual field during the operation, thus making the procedure even more “challenging”. In contrast, the visual surgical field of taTME is clearer due to the changed surgical approach, and the operative space is relatively larger [22].Regarding postoperative complications, for any new surgical method or approach, the incidence of complications should be controlled within the acceptable range of patients. The previously published preliminary results of an RCT, led by our center, showed an 8.1% incidence of anastomotic leakage for taTME [23]. Some other RCTs, such as COLOR II and CLASICC trials, reported that the incidence of anastomotic leakage in laTME was 13% and 10%, respectively. In this study, both groups showed a higher AL incidence rate since “challenging” patients may be at high risk of AL [24–29]. In males, it is considered that the pelvis tends to be longer, the sacrum is more curved, and the subpubic arch is narrower [8]. Furthermore, the male pelvic entrance is significantly narrower than that of the female [22]. Nevertheless, the incidence of anastomotic leakage in the taTME group was significantly lower compared with the laTME group (14.2% vs 25.2%, P=0.015), which is a rather remarkable finding. The reason for this result may be that taTME can retain more rectum. At the same time, because of the convenience of transanal operation, the anastomosis was strengthened routinely by 3-0 vicryl (Ethicon, Somerville, NJ, United States), after using the stapler. It is also worth noting that there were fewer patients with C-D grade III in the taTME group, which also reflects the improved safety of taTME surgery. In addition, taTME has a lower protective loop ileostomy rate (70.8% vs 92.5%, P<0.001), which can help to avoid a secondary operation. This is good news for patients both in terms of quality of life and postoperative recovery. Concerning other postoperative complications, the incidence of taTME was also lower than that of laTME, although the difference was not statistically significant. However, this trend explains why taTME leads to more speedy postoperative recovery; the median postoperative hospital stay for taTME was one day shorter than that for laTME. It is worth noting that according to the results of our previous report about the taTME learning curve [30], there are still individual surgeons in the taTME group who are impacted by the learning curve. However, compared with the laTME group, it still showed good postoperative results. Therefore, the prospects of implementing taTME for the treatment of “challenging” patients are highly promising.In the literature, the male gender has been acknowledged as a clinical variable correlated with difficult pelvic dissection and incomplete mesorectal excision, or positive CRM after laTME [31]. Several reports have shown that taTME is helpful to obtain high-quality specimens and lower rates of positive DRM and CRM, which can affect the patient survival and prognosis outlook [32]. This study could not demonstrate a significant difference in pathological outcomes between the two groups, although the positive CRM rate for the taTME group was lower than that for the laTME group (0% vs 1.9%). While the mesorectal quality was complete or near complete in both groups, the number of complete cases was higher in the taTME group. The above results are consistent with those of previous studies. In contrast to earlier findings [33, 34], DRM length was shorter in the taTME group than the laTME group, although the difference was statistically insignificant. This may be explained by the fact that, in the taTME group, while keeping a sufficient safety resection margin, a longer rectum can be retained to reconstruct the continuity of the intestine for anus preservation.When the Norwegian taTME collaborative group reported the results of their study on the local recurrence rate of taTME, it caused a huge controversy. Significantly higher local recurrence rates were obtained with taTME in 157 patients compared to the national average (7.6% vs 2.4%) [35]. In this study, the 2-year cumulative local recurrence rate was smaller in the taTME group as compared with the laTME group. Nonetheless, the difference did not reach statistical significance (1.1% vs 5.8%, P=0.22). These results indicate that the taTME may potentially reduce local recurrence rates with accurate DRM positioning and reducing tumor blocking effect, which shows its advantages for “challenging” patients. Although the rate of DFS and OS in the taTME group was higher, this study has not shown significant differences between the two groups. In fact, all of taTME, laTME, and open surgery TME are performed under the principles of TME. As long as the surgery is of high quality and obtains good histopathological results, long-term postoperative oncology outcomes, in theory, should be similar among these approaches with no significant difference. This has been proved by many studies, including some RCTs and meta-analyses [2, 36, 37]. Consequently, taTME may improve the long-term survival of “challenging” patients by higher quality TME.Certain limitations of this study need to be acknowledged. First, despite using PSM to decrease the selection bias, residual confounding may remain from other unmatched variables. Meanwhile, the remaining number of taTME at 24 months is only 39 out of 106. A large-scale RCT would be needed to prove the desirable effects of taTME. The long-term and functional results of an ongoing TaLaR trial will be due in 2021, which are much anticipated. Secondly, the sample size was small, which might increase the chance of type II errors. Furthermore, this study was based on a single center. Thus, results may not be representative. Another factor that may cause bias is the lower average BMI score for Asian patients than occidental patients, so high BMI was not included in this study’s definition of “challenging” patients.


## 5. Conclusions

The present study demonstrated that taTME might reduce the incidence of postoperative complications, especially of anastomotic leakage in these “challenging” patients. The lower rate of protective loop ileostomy subsequently reduces the blow to the patient’s second operation. Thus, taTME may be considered to have clear advantages for “challenging” patients.



---

*Source: 2387464-2022-02-27.xml*